A novel orally active gonadotropin-releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology

Reproductive medicine and biology

article

Michiko Hamada¹  Michiharu Horikawa¹  Chie Ensaka¹  Megumi Enomoto¹  Rena Ishii¹  Rena Toriumi¹  Naoyuki Tachibana¹  Yuji Taketani¹ 

[1]Women’s Clinic Oizumigakuen

[2]Artemis Women’s Hospital

关键词: cetrorelix;    controlled ovarian stimulation;    Gonadotropin-releasing hormone antagonist;    pregnancy rate;    relugolix;   

DOI  :  10.1002/rmb2.12424

学科分类：工业工程学

来源: Wiley

【 摘 要 】

Purpose To evaluate the efficacy of an oral gonadotropin-releasing hormone antagonist (GnRH Ant), relugolix (R), for assisted reproductive technology (ART). Methods We enrolled women undergoing ART using a GnRH Ant for controlled ovarian stimulation. We compared R; 20 mg/day with cetrorelix acetate (C); 0.125 mg. C was administered to 88 women in 2019, and R to 93 women in 2020. Clinical outcomes associated with ART were assessed in both groups. Results The luteinizing hormone levels on the day of human chorionic gonadotropin injection in the R group (1.26 ± 0.93 IU/L) were significantly lower than those in the C group (2.85 ± 3.02 IU/L). There were no cases in which egg retrieval was canceled in both groups. The total doses of gonadotropins administered were greater in the R group compared with the C group. The number of days of GnRH Ant administration in the R group (1.71 ± 0.57 days) was significantly longer compared with the C group (1.48 ± 0.58 days). The number of oocytes collected, fertilization rates, and pregnancy rates (R; 47.1% vs C; 45.8%) did not differ between the two groups. Conclusion An orally active GnRH Ant, relugolix, when used in controlled ovarian stimulation for ART, showed comparable clinical outcomes with cetrorelix.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND